Literature DB >> 22082758

MicroRNAs in the pathogenesis of cancer.

Francesca Lovat1, Nicola Valeri, Carlo M Croce.   

Abstract

MicroRNAs (miRs) are small (19-25 nucleotides) non-protein-coding RNAs involved in development, differentiation, and aging; they act by inducing messenger RNA (mRNA) silencing through degradation, and post-transcriptional or decoy activity. miR profiles of human solid and hematologic malignancies have highlighted their potential value as tumor markers in cancer patient management. Different experimental lines of evidence have confirmed that deregulation of miRs not only results as consequence of cancer progression but also directly promotes tumor initiation and progression in a cause-effect manner. These findings reveal a potential and appealing role for miRs as cancer therapeutic targets. This review focuses on the causes and consequences of miR deregulation in carcinogenesis and tumor progression. The work aims at providing the molecular bases for the understanding of the potential role of miRs in the translational and clinical setting.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22082758     DOI: 10.1053/j.seminoncol.2011.08.006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  107 in total

Review 1.  Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.

Authors:  B Stefanska; H Karlic; F Varga; K Fabianowska-Majewska; Ag Haslberger
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas.

Authors:  Edward A Ratovitski
Journal:  Cell Cycle       Date:  2014-01-06       Impact factor: 4.534

3.  MicroRNA-630 is a prognostic marker for patients with colorectal cancer.

Authors:  Dake Chu; Jianyong Zheng; Jipeng Li; Yunming Li; Jian Zhang; Qingchuan Zhao; Weizhong Wang; Gang Ji
Journal:  Tumour Biol       Date:  2014-07-01

4.  Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer.

Authors:  Zhaofeng Chen; Xiaoguang Liu; Zenan Hu; Yuping Wang; Min Liu; Xiaojun Liu; Hailong Li; Rui Ji; Qinhong Guo; Yongning Zhou
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

Review 5.  Molecular mechanisms of pharmacological doses of ascorbate on cancer cells.

Authors:  Sascha Venturelli; Tobias W Sinnberg; Heike Niessner; Christian Busch
Journal:  Wien Med Wochenschr       Date:  2015-06-12

6.  Influence of quercetin-rich food intake on microRNA expression in lung cancer tissues.

Authors:  Tram K Lam; Stephanie Shao; Yingdong Zhao; Francesco Marincola; Angela Pesatori; Pier Alberto Bertazzi; Neil E Caporaso; Ena Wang; Maria Teresa Landi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-03       Impact factor: 4.254

Review 7.  Epigenetic effects of green tea polyphenols in cancer.

Authors:  Susanne M Henning; Piwen Wang; Catherine L Carpenter; David Heber
Journal:  Epigenomics       Date:  2013-12       Impact factor: 4.778

Review 8.  MicroRNAs in the control of metastatic bone disease.

Authors:  Gillian Browne; Hanna Taipaleenmäki; Gary S Stein; Janet L Stein; Jane B Lian
Journal:  Trends Endocrinol Metab       Date:  2014-05-05       Impact factor: 12.015

9.  NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.

Authors:  Francesco Marampon; Silvia Codenotti; Francesca Megiorni; Andrea Del Fattore; Simona Camero; Giovanni Luca Gravina; Claudio Festuccia; Daniela Musio; Francesca De Felice; Valerio Nardone; Anna Natalizia Santoro; Carlo Dominici; Alessandro Fanzani; Luigi Pirtoli; Antonella Fioravanti; Vincenzo Tombolini; Sara Cheleschi; Paolo Tini
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-30       Impact factor: 4.553

10.  MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.

Authors:  Jing Liu; Kai-Hua Lu; Zhi-Li Liu; Ming Sun; Wei De; Zhao-Xia Wang
Journal:  BMC Cancer       Date:  2012-11-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.